Would you like to contribute to this site?
IBS Menu
Submit an Article
Submit a Tip
Place your Ad
Add URL
IBS Questions?
Contact Us
Related Topics:
Child Irritable Bowel Syndrome
Ibs
Ibs And Pregnancy
Ibs Diagnosis
Ibs In Child
Ibs Syndrome
Inflammatory Bowel
Inflammatory Bowel Disorder
Information On Ibs
Irritable Bowel Movement
Irritable Bowel Syndrome Children
Irritable Bowel Syndrome In Child
What Is Ibs
What Is Irritable Bowel
Anxiety And Ibs
Ibs Home
Ibs Tales
Irritable Bowel Syndrome Uk
Other Channels:
|
 |
|
|
|
|
|
|
|
|
Recent Questions and Answers
|
|
|
|
|
|
|
|
Recent Irritable Bowel Syndrome In Child News:
|
|
|
When Salix Pharmaceuticals (NASDAQ:SLXP) disclosed that the U.S. Food and Drug Administration would not approve its drug Xifaxan for the new indication of irritable bowel syndrome, the gastrointestinal treatments company made clear it believed its drug met all of the targets needed for approval. Now we’re starting to see how much more ground the drug [...]
The King of Prussia, PA company intends to remain the resource for print and direct marketing campaigns.King of Prussia, PA (PRWEB) November 04, 2011 George Schnyder, owner and CEO of IBS Direct, announced that his company has acquired Mars Graphic Services, Inc. The transaction is effective November 1, 2011. Based in King of Prussia, PA, IBS Direct offers high-quality printing solutions, direct ...
SARASOTA, FL - Sarasota County, Fla., Operations and Maintenance (O&M) Fleet Services recently outsourced its parts room, which had more than $350,000 of inventory monthly with yearly purchases totaling more than $1 million.
A patient's viewpoint of the severity of irritable bowel syndrome (IBS) symptoms can be influenced not only by physical symptoms of IBS but broader psychological problems, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.
Salix Pharmaceuticals Ltd. Posted on:17 Nov 11 Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Gastrointestinal Drugs Advisory Committee of the FDA supports the Salix/FDA developed proposed design of a clinical trial to evaluate the safety, efficacy and durability of response with repeat treatment cycles of XIFAXAN® (rifaximin) for irritable bowel syndrome with diarrhea (IBS).
| |
| |
|
|
|
Additional Irritable Bowel Syndrome In Child Resources:
|
|
|
|
|
|
|
|
|
Want your site featured on this page?
|
|
 |
|